Streamlining US health care business has raised unique privacy concerns. Bills and explanations of benefits contain protected health information that could be disclosed to someone other than the patient.
AMA J Ethics. 2016;18(3):279-287. doi:
10.1001/journalofethics.2016.18.3.pfor4-1603.
Mary Anderlik Majumder, JD, PhD and Christi J. Guerrini, JD
Amendments to the Common Rule and Health Insurance Portability and Accountability Act (HIPAA) raise questions about broad consent and sale of health data.
AMA J Ethics. 2016;18(3):288-298. doi:
10.1001/journalofethics.2016.18.3.pfor5-1603.
Efrat Lelkes, MD, Angira Patel, MD, MPH, Anna Joong, MD, and Jeffrey G. Gossett, MD
Current policy requires separate informed consent for some Public Health Service increased-risk donors, and this can make shared decision making harder.
AMA J Ethics. 2020;22(5):E401-407. doi:
10.1001/amajethics.2020.401.
Upcoding and misrepresenting clinical information constitute fraud, cost a lot, and can result in patient harm and unnecessary procedures and prescriptions.
AMA J Ethics. 2020;22(3):E221-231. doi:
10.1001/amajethics.2020.221.
Underlying ideological foundations of stigma and equipment inadequacy include thin-centrism and inadequate representation of fat people in health care organizational leadership.
AMA J Ethics. 2023;25(7):E528-534. doi:
10.1001/amajethics.2023.528.
The separation of dental and medical care is a medical ethics issue because it negatively impacts vulnerable populations who lack access to dental care.
AMA J Ethics. 2016;18(9):861-868. doi:
10.1001/journalofethics.2016.18.9.peer1-1609.
The meaning of “disability” has shifted with US public policy changes over time. People with disability are protected under civil rights law, and open questions remain about whether and when policy-level interventions and reasonable accommodations create equal opportunity.
AMA J Ethics. 2016;18(10):1025-1033. doi:
10.1001/journalofethics.2016.18.10.pfor2-1610.
Susanne Sheehy, BM BCh, MRCP, DTM&H and Joel Meyer, BM BCh, MRCP
The decline in numbers of healthy volunteers who participate in clinical trials has the potential to become a key rate-limiting factor in vaccine development.